AZN.ST - AstraZeneca PLC
NEXT EARNINGS:
Apr 29, 2026
EPS Est: $21.54
|
Rev Est: $130.6B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Market Cap:
2.90T
Volume:
284,894
Avg Volume:
332,320
52 Week Range:
1226-1915
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.19
Last Dividend:
$29.20
Exchange:
STO
Country:
GB
Employees:
94,300
IPO Date:
2000-01-03
EPS (TTM):
6.60
P/E Ratio:
27.94
Revenue (TTM):
58.74B
Total Assets:
114.07B
Total Debt:
29.62B
Cash & Equiv:
5.71B
Rev Growth (5Y):
17.2%
EPS Growth (5Y):
22.0%
FCF Growth (5Y):
31.6%
ROCE:
16.9%
Debt/Equity:
0.61
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-10 | $13.72 | $21.37 | -35.8% | $142.9B | $130.0B | +9.9% |
| 2025-11-06 | $15.22 | $19.99 | -23.9% | $142.5B | $147.0B | -3.1% |
| 2025-07-29 | $15.04 | $22.44 | -33.0% | $138.4B | $142.5B | -2.9% |
| 2025-04-29 | $18.70 | $21.17 | -11.7% | $136.0B | $135.2B | +0.6% |
| 2025-02-06 | $10.62 | $23.00 | -53.8% | $164.7B | $145.9B | +12.9% |
| 2024-11-12 | $9.50 | $239.75 | -96.0% | $140.7B | $1.5T | -90.9% |
| 2024-07-25 | $13.06 | $226.91 | -94.2% | $136.8B | $1.5T | -90.7% |
| 2024-03-31 | $15.06 | $20.46 | -26.4% | $136.7B | $126.3B | +8.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.74B | 54.07B | 45.81B | 44.35B | 37.42B | 26.62B | 24.38B | 22.09B | 22.46B | 23.00B | 24.71B | 26.09B |
| Net Income | 10.22B | 7.04B | 5.96B | 3.29B | 112.00M | 3.20B | 1.33B | 2.15B | 3.00B | 3.50B | 2.83B | 1.23B |
| EPS | 6.60 | 4.54 | 3.81 | 2.12 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.77 | 2.23 | 0.98 |
| Total Assets | 114.07B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B | 61.38B | 60.65B | 63.35B | 62.53B | 60.12B | 58.59B |
| Total Debt | 29.62B | 30.11B | 28.62B | 29.23B | 30.78B | 20.38B | 18.23B | 19.11B | 17.81B | 16.81B | 15.05B | 10.84B |
| Cash & Equivalents | 5.71B | 5.49B | 5.84B | 6.17B | 6.33B | 7.83B | 5.37B | 4.83B | 3.32B | 5.02B | 6.24B | 6.36B |
| Operating Cash Flow | 14.57B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B | 2.97B | 2.62B | 3.58B | 4.14B | 3.32B | 7.06B |
| Free Cash Flow | 8.67B | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B | 509.00M | 1.25B | 1.96B | 1.83B | 536.00M | 4.31B |
| FCF per Share | 5.59 | 4.69 | 4.20 | 4.68 | 2.65 | 1.67 | 0.39 | 0.98 | 1.55 | 1.45 | 0.42 | 3.41 |
| Book Value | 48.67B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B | 13.13B | 12.47B | 14.96B | 14.85B | 18.49B | 19.63B |
| Cash & ST Investments | 5.74B | 5.53B | 5.86B | 6.41B | 6.40B | 7.99B | 6.22B | 5.68B | 4.55B | 5.90B | 6.85B | 7.16B |
| ROC Equity | 0.21 | 0.17 | 0.15 | 0.09 | 0.00 | 0.20 | 0.10 | 0.17 | 0.20 | 0.24 | 0.15 | 0.06 |